Erick Gamelin

About Erick Gamelin

Erick Gamelin, M.D., Ph.D., is Acrivon Therapeutics’ Chief Development Officer (since January 2024) and previously served as Chief Medical Officer (since March 2021), reflecting a senior leadership role in ACRV’s clinical development and translational strategy . He is a medical oncologist and former professor of Medical Oncology, previously CEO of a national University Cancer Center (ICO) in France, a Knight of the French National Order of Merit, and a co‑author of 135+ peer‑reviewed articles; he earned a Ph.D. in molecular pharmacology from Bordeaux University and completed post‑doctoral studies at the NIH . As of the 2025 proxy, he is 68 years old and continues to be listed among executive officers (Chief Development Officer) . Company‑level TSR, revenue, or EBITDA performance metrics tied specifically to his tenure are not disclosed in the proxy materials reviewed .

Past Roles

External Roles

Fixed Compensation

Gamelin was not a Named Executive Officer (NEO) in the 2024 or 2025 proxy statements; his base salary, target bonus, and actual bonus are not itemized in the Summary Compensation Tables (which cover CEO Blume‑Jensen, EVP Masson, and COO Devroe for 2024) .

Performance Compensation

• ACRV’s executive program uses annual cash incentives tied to corporate and individual objectives; the Board determined 2024 corporate goals were achieved and bonuses were paid in early 2025, but the proxy does not disclose Gamelin’s specific targets or payout amounts (he is not a NEO) .
• Equity program mixes stock options and RSUs to align with long‑term performance and retention; grants are discretionary and broadly used across employees .
• Governance note: The company disclosed that certain option grants made March 1, 2024 to NEOs vest 25% on March 3, 2025, with the remainder in 36 equal monthly installments; these terms are illustrative of company practice but Gamelin’s specific award terms were not itemized in the proxy .

Equity Ownership & Alignment

• Individual beneficial ownership for Gamelin is not separately reported in the beneficial ownership tables (which list directors and NEOs); accordingly, specific share counts, percent ownership, and pledged shares status are not disclosed for him in the proxy .
• Section 16 compliance: The 2025 proxy noted late Form 4 filings on November 27, 2024 (including for Erick Gamelin) to report March 1, 2024 option grants, citing administrative oversight .
• Company context on equity: As of December 31, 2024, equity compensation plans covered 4,485,546 outstanding options (weighted average exercise price $7.04) and 975,559 unvested RSUs, with 2,401,347 shares remaining available for future issuance, indicating broad‑based equity participation that can influence insider supply over time .

Employment Terms

• The 2025 proxy provides detailed employment and severance terms for the CEO, EVP Masson, and COO Devroe; it does not disclose an employment agreement summary or change‑in‑control economics specific to Erick Gamelin .
• Accordingly, severance multiples, bonus treatment, and vesting acceleration for Gamelin are not available in the reviewed proxy materials .

Risk Indicators and Red Flags

• Administrative issue: Late Form 4 filing (Nov 27, 2024) to report March 1, 2024 option grant, along with several other insiders; the company attributes this to an administrative oversight .
• Related‑party transactions: The company describes its related‑party transaction policy; no Gamelin‑specific related‑party transactions are disclosed in the sections reviewed .

Performance & Track Record

• Credible execution background: Medical oncologist with deep clinical development leadership across Step Pharma, Dynavax, MacroGenics, Pfizer, and significant academic credentials; recognized with the French National Order of Merit; co‑authored 135+ peer‑reviewed articles, signaling domain expertise and scientific leadership .
• Internal mobility: Elevated from CMO (Mar 2021) to CDO (Jan 2024), maintaining continuity over development strategy through organizational transitions .

Investment Implications

• Alignment and incentives: While individual cash compensation and ownership data for Gamelin are not disclosed, ACRV’s heavy use of equity across executives and employees (options and RSUs with multi‑year vesting) suggests ongoing retention incentives; absent Gamelin‑specific holdings, insider supply risk from his sales cannot be quantified from the proxy alone .
• Retention risk assessment: Lack of publicly disclosed employment terms for Gamelin (vs. detailed CEO/EVP/COO terms) creates limited transparency on his severance/change‑in‑control protection; however, sustained senior roles since 2021 and internal elevation to CDO indicate organizational reliance on his clinical leadership .
• Trading signals: The noted late Form 4 for March 1, 2024 option grants is an administrative issue rather than a sale signal; without Form 4 sale data disclosed in the proxy, no insider‑selling pressure can be inferred for Gamelin specifically from these materials .